EdgarLookup

Xtant Medical Holdings, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Xtant Medical Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Financials Insiders
-30.8%
Profit Margin
Net income ÷ revenue
-17.5%
Return on Assets
Net income ÷ assets
1.18x
Debt-to-Equity
Total liabilities ÷ equity
-17.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2020 Dec 31, 2020 $53.34M Feb 24, 2021
FY2020 Dec 31, 2019 $64.68M Feb 24, 2021
FY2019 Dec 31, 2018 $72.20M Mar 5, 2020
FY2018 Dec 31, 2017 $82.61M Apr 1, 2019
FY2011 Dec 31, 2011 $30.15M Mar 29, 2012
FY2011 Dec 31, 2010 $15.42M Mar 29, 2012

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $117.27M Mar 6, 2025
FY2024 Dec 31, 2023 $91.30M Mar 6, 2025
FY2023 Dec 31, 2022 $57.97M Apr 1, 2024
FY2022 Dec 31, 2021 $55.26M Mar 7, 2023
FY2021 Dec 31, 2020 $53.34M Mar 8, 2022
FY2020 Dec 31, 2019 $64.68M Feb 24, 2021
FY2019 Dec 31, 2018 $72.20M Mar 5, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $82.61M Apr 5, 2018
FY2017 Dec 31, 2016 $90.00M Apr 5, 2018
FY2016 Dec 31, 2015 $59.35M Mar 29, 2017
FY2015 Dec 31, 2014 $35.33M Mar 24, 2016
FY2014 Dec 31, 2013 $33.07M Mar 18, 2015
FY2013 Dec 31, 2012 $32.98M Mar 27, 2014
FY2012 Dec 31, 2011 $30.15M Mar 27, 2013
FY2011 Dec 31, 2010 $15.21M Mar 29, 2012

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($16.45M) Mar 6, 2025
FY2024 Dec 31, 2023 $660.0K Mar 6, 2025
FY2023 Dec 31, 2022 ($8.49M) Apr 1, 2024
FY2022 Dec 31, 2021 ($4.85M) Mar 7, 2023
FY2021 Dec 31, 2020 ($7.02M) Mar 8, 2022
FY2020 Dec 31, 2019 ($8.22M) Feb 24, 2021
FY2019 Dec 31, 2018 ($70.10M) Mar 5, 2020
FY2018 Dec 31, 2017 ($52.41M) Apr 1, 2019
FY2017 Dec 31, 2016 ($19.49M) Apr 5, 2018
FY2016 Dec 31, 2015 ($2.17M) Mar 29, 2017

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($12.07M) Mar 6, 2025
FY2024 Dec 31, 2023 ($10.16M) Mar 6, 2025
FY2023 Dec 31, 2022 ($6.76M) Apr 1, 2024
FY2022 Dec 31, 2021 ($3.85M) Mar 7, 2023
FY2021 Dec 31, 2020 ($751.0K) Mar 8, 2022
FY2020 Dec 31, 2019 ($2.25M) Feb 24, 2021
FY2019 Dec 31, 2018 ($60.08M) Mar 5, 2020
FY2018 Dec 31, 2017 ($37.83M) Apr 1, 2019
FY2017 Dec 31, 2016 ($7.55M) Apr 5, 2018
FY2016 Dec 31, 2015 ($12.08M) Mar 29, 2017

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $93.84M Mar 6, 2025
FY2024 Dec 31, 2023 $92.61M Mar 6, 2025
FY2023 Dec 31, 2022 $60.23M Apr 1, 2024
FY2022 Dec 31, 2021 $54.69M Mar 7, 2023
FY2021 Dec 31, 2020 $41.47M Mar 8, 2022
FY2020 Dec 31, 2019 $43.16M Feb 24, 2021
FY2019 Dec 31, 2018 $46.42M Mar 5, 2020
FY2018 Dec 31, 2017 $105.71M Apr 1, 2019
FY2017 Dec 31, 2016 $144.10M Apr 5, 2018
FY2016 Dec 31, 2015 $141.03M Mar 29, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $50.87M Mar 6, 2025
FY2024 Dec 31, 2023 $41.26M Mar 6, 2025
FY2023 Dec 31, 2022 $26.06M Apr 1, 2024
FY2022 Dec 31, 2021 $23.81M Mar 7, 2023
FY2021 Dec 31, 2020 $26.95M Mar 8, 2022
FY2020 Dec 31, 2019 $87.36M Feb 24, 2021
FY2019 Dec 31, 2018 $90.19M Mar 5, 2020
FY2018 Dec 31, 2017 $164.40M Apr 1, 2019
FY2017 Dec 31, 2016 $151.17M Apr 5, 2018
FY2016 Dec 31, 2015 $132.15M Mar 29, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $42.96M Mar 6, 2025
FY2024 Dec 31, 2023 $51.35M Mar 6, 2025
FY2024 Dec 31, 2022 $34.17M Mar 6, 2025
FY2023 Dec 31, 2021 $30.88M Apr 1, 2024
FY2022 Dec 31, 2020 $14.51M Mar 7, 2023
FY2021 Dec 31, 2019 ($44.21M) Mar 8, 2022
FY2020 Dec 31, 2018 ($43.77M) Feb 24, 2021
FY2019 Dec 31, 2017 ($58.70M) Mar 5, 2020
FY2018 Dec 31, 2016 ($7.07M) Apr 1, 2019
FY2017 Dec 31, 2015 $8.88M Apr 5, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 0 Mar 6, 2025
FY2024 Dec 31, 2023 0 Mar 6, 2025
FY2023 Dec 31, 2022 0 Apr 1, 2024
FY2022 Dec 31, 2021 0 Mar 7, 2023
FY2021 Dec 31, 2020 0 Mar 8, 2022
FY2020 Dec 31, 2019 0 Feb 24, 2021
FY2019 Dec 31, 2018 (5) Mar 5, 2020
FY2018 Dec 31, 2017 (34) Apr 1, 2019
FY2017 Dec 31, 2016 (18) Apr 5, 2018
FY2016 Dec 31, 2015 0 Mar 29, 2017

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 0 Mar 6, 2025
FY2024 Dec 31, 2023 0 Mar 6, 2025
FY2023 Dec 31, 2022 0 Apr 1, 2024
FY2022 Dec 31, 2021 0 Mar 7, 2023
FY2021 Dec 31, 2020 0 Mar 8, 2022
FY2020 Dec 31, 2019 0 Feb 24, 2021
FY2019 Dec 31, 2018 (5) Mar 5, 2020
FY2018 Dec 31, 2017 (34) Apr 1, 2019
FY2017 Dec 31, 2016 (18) Apr 5, 2018
FY2016 Dec 31, 2015 0 Mar 29, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $6.20M Mar 6, 2025
FY2024 Dec 31, 2023 $5.72M Mar 6, 2025
FY2023 Dec 31, 2022 $20.30M Apr 1, 2024
FY2022 Dec 31, 2021 $18.24M Mar 7, 2023
FY2021 Dec 31, 2020 $2.34M Mar 8, 2022
FY2020 Dec 31, 2019 $5.24M Feb 24, 2021
FY2019 Dec 31, 2018 $6.80M Mar 5, 2020
FY2018 Dec 31, 2017 $2.86M Apr 1, 2019
FY2018 Dec 31, 2016 $2.58M Apr 1, 2019
FY2017 Dec 31, 2015 $6.37M Apr 5, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $22.04M Mar 6, 2025
FY2024 Dec 31, 2023 $17.17M Mar 6, 2025
FY2023 Dec 31, 2022 $9.69M Apr 1, 2024
FY2022 Dec 31, 2021 $11.79M Mar 7, 2023
FY2020 Dec 31, 2019 $76.24M Feb 24, 2021
FY2019 Dec 31, 2018 $77.94M Mar 5, 2020
FY2018 Dec 31, 2017 $137.96M Apr 1, 2019
FY2017 Dec 31, 2016 $119.22M Apr 5, 2018
FY2016 Dec 31, 2015 $110.67M Mar 29, 2017